Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men.

What Was Tested

This randomized controlled trial looks at Bradykinin and Acetylcholine.

The purpose of this study was to investigate in vivo the effects of acute systemic inflammation on the endogenous fibrinolytic capacity in men.

Why It Was Studied

Systemic inflammation and endogenous fibrinolysis play a major role in the pathogenesis of coronary artery disease.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

In a double-blind randomized placebo-controlled crossover trial, the researchers administered a mild inflammatory stimulus, Salmonella typhi vaccine, or saline placebo to eight healthy men on two separate occasions.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Bradykinin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Bradykinin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Bradykinin could be set against what happens without it.

In the crossover set-up each of the participants took both Bradykinin and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Acetylcholine, Brachial Artery, Bradykinin, Coronary Artery Disease, Endothelium, Vascular, Inflammation and Nitroprusside.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin and Acetylcholine.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Journal of the American College of Cardiology), a journal based in United States.

More context: the related Bradykinin library page, all human trials.